Adcytherix Becomes Clinical-Stage With First ADCX-020 Dosing and Expanded Leadership Bench

New updates have been reported about Adcytherix.

Adcytherix has transitioned into a clinical-stage biopharmaceutical company by dosing the first patient in its Phase 1a/b trial of ADCX-020, the lead asset from its ADCX Engine platform, in patients with advanced solid tumors. The open-label study will assess safety, pharmacokinetics, pharmacodynamics, and initial anti-tumor activity through a dose-escalation phase followed by dose optimization and targeted cohort expansion in relapsed or refractory disease settings.

ADCX-020 is built around a stable linker and an exatecan-derived topoisomerase I inhibitor, aiming to overcome limitations of earlier antibody-drug conjugates by improving the therapeutic index and enabling use across multiple tumor types. Management highlights that first-patient dosing, achieved in under two years since the company’s founding, provides the first clinical validation of its ADC strategy and demonstrates a capital-efficient development model that can be replicated across its pipeline.

To support this next phase of growth, Adcytherix has reinforced its senior team with Paul Jackson appointed Chief Operating Officer and Magali Gibou named Chief Regulatory & Quality Officer, adding depth in ADC platform development, operational scale-up, and global regulatory strategy. In parallel, the company strengthened governance with the appointment of industry veteran Simon Sturge as Independent Chairman of the Board, positioning the firm for more complex clinical, regulatory, and partnership activities.

Backed by a €105 million Series A round, Adcytherix reports a solid financial base to progress ADCX-020 through early clinical development while simultaneously advancing additional ADC programs targeting clinically validated antigens and novel payload mechanisms derived from approved oncology drugs. The company, headquartered in Marseille with U.S. and Netherlands subsidiaries, is explicitly pursuing a diversified ADC franchise across multiple indications, with the stated ambition to become a global leader in next-generation ADC therapeutics and to translate its platform into de-risked, differentiated assets attractive to partners and investors.